Table of Contents
Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis
Related Topics
Astaxanthin Market Size Peptide Antibiotics Market Size Inhalable Biologics Market Size Vitamin K2 Market SizeGlobal Blockbuster Oncology Brands Market Size to Exceed USD 87.80 Billion by 2033
According to a research report published by Spherical Insights & Consulting, The Global Blockbuster Oncology Brands Market Size Expected to Grow from 40.10 Billion in 2023 to USD 87.80 Billion by 2033, at a CAGR of 8.15% during the forecast period 2023-2033.
Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Blockbuster Oncology Brands Market Size, Share, and COVID-19 Impact Analysis, By Brands (Opdivo, Keytruda, Perjeta, and Ibrance), By Treatment (Lung Cancer and Lymphoma), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033
Blockbuster oncology brands market is a term used to describe the worldwide industry engaged in high-grossing oncology drugs that record annual sales of $1 billion-plus. These medications are central in cancer management and treatment, such as targeted therapies, immunotherapies, chemotherapy, and hormone therapies, and significantly enhance survival rates and patient outcomes for many types of cancers. Moreover, the blockbuster oncology brands market is led by increasing incidence of cancer, improvements in targeted therapy and immunotherapy, augmented R&D spending, regulatory approval, rising demand for personalized therapy, and widening healthcare infrastructure across the globe. The market is also favored by pharmaceutical partnerships, innovation breakthroughs in targeted oncology, growth of biosimilar adoption, patient access initiatives, growth in healthcare spending, and increasing clinical trials for emerging cancer therapies. However, the blockbuster oncology brands Market is subject to constraints like expensive drugs, high regulatory approval hurdles, patent loss, biosimilar competition, availability issues in developing markets, and side effects linked with cancer treatment.
The Keytruda segment accounted for the largest share of the global blockbuster oncology brands market in 2023 and is anticipated to grow at a significant CAGR during the forecast period.
Based on brands, the global blockbuster oncology brands market is divided into opdivo, Keytruda, Perjeta, Ibrance. Among these, the Keytruda segment accounted for the largest share of the global Blockbuster Oncology Brands market in 2023 and is anticipated to grow at a significant CAGR during the forecast period. This is led by its broad adoption across various forms of cancer, such as lung, melanoma, head & neck, and bladder cancers. With strong clinical response, increasing indications, and increasing globalization, Keytruda, the top PD-1 immune checkpoint inhibitor, is the market benchmark above Opdivo, Perjeta, and Ibrance.
The lung cancer segment accounted for a substantial share of the global blockbuster oncology Brands market in 2023 and is anticipated to grow at a rapid pace during the projected period.
On the basis of the treatment, the global blockbuster oncology brands market is divided into lung cancer and lymphoma. Among these, the lung cancer segment accounted for a substantial share of the global blockbuster oncology brands market in 2023 and is anticipated to grow at a rapid pace during the projected period. This is powered by the large incidence of non-small cell lung cancer (NSCLC) and the extensive use of immune checkpoint inhibitors such as Keytruda and Opdivo. Improvements in targeted therapies and early detection techniques also enhance lung cancer treatment leadership over lymphoma.
North America is projected to hold the largest share of the global blockbuster oncology brands market over the projected period.
North America is projected to hold the largest share of the global blockbuster oncology brands market over the projected period. This is led by a high incidence of cancer, robust healthcare infrastructure, cutting-edge R&D, and high use of immunotherapies and targeted therapies. The presence of large pharma players, positive reimbursement policies, and growing FDA approvals further reinforce the region's market leadership.
Asia Pacific is expected to grow at the fastest CAGR of the global blockbuster oncology brands market during the projected period. This is driven by growing cancer incidence, rising healthcare spending, widening access to innovative therapies, and expanding clinical trials. Government policies, enhanced healthcare infrastructure, and a rise in biosimilar uptake further drive the region's fast market growth.
Company Profiling
Major vendors in the global blockbuster oncology brands market are Novartis AG, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., GSK plc, F. Hoffmann-La Roche Ltd, and others.
Key Target Audience
Recent Development
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global blockbuster oncology brands market based on the below-mentioned segments:
Global Blockbuster Oncology Brands Market, By Brands
Global Blockbuster Oncology Brands Market, By Treatment
Global Blockbuster Oncology Brands Market, By Regional
May 2025 - The Global Anti Fogging Agent for Cars Market Size is Expected to Grow from USD 620.24 Million in 2023 to USD 1126.41 Million by 2033, Growing at a CAGR of 6.15% during the forecast period 2023-2033
May 2025 - The Global Uveitis Treatment Market Size Expected to Grow from 2.13 Billion in 2023 to USD 5.23 Billion by 2033, at a CAGR of 9.40% during the forecast period 2023-2033.
May 2025 - The Global Astaxanthin Market Size Expected to Grow from 1.21 Billion in 2023 to USD 4.69 Billion by 2033, at a CAGR of 14.51% during the forecast period 2023-2033.
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
+1 303 800 4326 +91 9561448932 emailsales@sphericalinsights.com
